KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAmortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Neogenomics (NEO) Other financing activities (2017 - 2019)

Neogenomics (NEO) has disclosed Other financing activities for 5 consecutive years, with $8000.0 as the latest value for Q4 2019.

  • For the quarter ending Q4 2019, Other financing activities changed N/A year-over-year to $8000.0, compared with a TTM value of $105000.0 through Dec 2020, changed 0.0%, and an annual FY2019 reading of $1.1 million, up 83.85% over the prior year.
  • Other financing activities was $8000.0 for Q4 2019 at Neogenomics, down from $97000.0 in the prior quarter.
  • Across five years, Other financing activities topped out at $576000.0 in Q2 2018 and bottomed at -$112000.0 in Q3 2017.
  • Average Other financing activities over 4 years is $129666.7, with a median of $97000.0 recorded in 2016.
  • Peak annual rise in Other financing activities hit 15.46% in 2017, while the deepest fall reached 15.46% in 2017.
  • Year by year, Other financing activities stood at $97000.0 in 2016, then crashed by 215.46% to -$112000.0 in 2017, then soared by 614.29% to $576000.0 in 2018, then crashed by 98.61% to $8000.0 in 2019.
  • Business Quant data shows Other financing activities for NEO at $8000.0 in Q4 2019, $97000.0 in Q3 2019, and $576000.0 in Q2 2018.